1. Background {#sec1-1}
=============

Due to the progress in genetic engineering, green plants have emerged as ideal platforms for production of recombinant vaccine during recent decades. Various antigens relating to a large number of animal and human diseases have been studied in different plant species for the purpose of producing recombinant vaccines. Despite the unique advantages of plant systems as green factories for production of recombinant vaccines, there are some major hurdles that have prevented commercial production of plant-based vaccines ([@ref1]). One of the major problems with recombinant vaccines is the inefficacy of the expressed antigens for induction of immune response in animal hosts ([@ref2]). Oral delivery of plant-based recombinant vaccines is a potential alternative to injection, owing to the low cost and ease of administration. Plant-based vaccines are free of human and animal diseases and, therefore, can reduce the costs of screening for viral and microbial contamination. In addition, the chance of acquiring mucosal immunity against infectious agents that enter the body across a mucosal surface is increased with oral vaccines ([@ref3]). Despite numerous advantages of green plants over other heterologous expression systems such as bacteria, yeast and insect cell culture, low expression level of the antigen in plant hosts is still a main challenge for commercialization of plant-based recombinant vaccines ([@ref4]). To overcome this problem, various strategies such as host-specific codon optimization, inclusion of 5′-untranslated-leader sequences, insertion of introns within coding region, and the application of signal peptide have been proposed and applied in genetic transformation experiments with varying degrees of success ([@ref1]). The main problem in the application of orally-delivered immunogenic proteins is that some proteins are degraded after ingestion and some immunogens may not be recognized efficiently at mucosal-immune-effector sites in the gut. Plant-derived vaccines have demonstrated the ability to induce both systemic and mucosal immune responses ([@ref5]).

Newcastle disease (ND) has been a major target for development of veterinary vaccines during recent decades and many attempts have been made to develop efficient vaccines against ND via genetic engineering in higher plants ([@ref6]). In our previous work, we successfully transferred and expressed Hemagglutinin-Neuraminidase (HN) and Fusion (F) epitopes of Newcastle Disease Virus (NDV) in tobacco seedlings ([@ref7]). Herein, we report induction of immune response in animal model using recombinant HN and F epitopes as potential recombinant vaccine against ND.

2. Objectives {#sec1-2}
=============

In the present investigation, we report subcutaneous administration of a fusion HN-F peptide and subsequent immune response induction in animal model. The fusion peptide includes four tandem repeat of HN epitope (encoding amino acids 346-353) with 96bp length followed by three tandem repeat of F epitope (encoding amino acids 65-81) with 153bp length.

3. Materials and Methods {#sec1-3}
========================

3.1. Plant Transformation {#sec2-1}
-------------------------

Gene construct design, Construction of Binary Vector and plant transformation, and verification of putative transgenic lines have been described elsewhere ([@ref7]).

3.2. Selection of Transgenic Lines with the Highest Expression {#sec2-2}
--------------------------------------------------------------

Real-time PCR and ELISA assays were performed to screen the putative transgenic lines to select those with the highest expression.

### 3.2.1. Real-Time PCR {#sec3-1}

Expression of the synthetic gene was evaluated in transcription level by real-time PCR assay. Total RNA was extracted from 500 mg of leaf tissue using RNX-Plus according to manufacturers' instruction. Complementary DNA (cDNA) was synthesized via reverse transcription using oligo (dT)~20~ primer. The resulting cDNA mixtures were used as templates for the real-time PCR. Expression of the synthetic gene was quantitatively analyzed using a real-time PCR system (BioRad). Real-time PCR was carried out in a 20 μL reaction volume containing 0.5 μM of each primer and 10 μL of SYBR Green real-time PCR master mix (Genet Bio, South Korea). Quantitative real-time PCR experiments were performed in duplicate for each sample. Forward and reverse primers for real-time PCR were 5´-GCCACACCTCGCACATTG 3´and 5´ GCCAGCATCACCATTCTTG-3´, respectively.

### 3.2.2. ELISA {#sec3-2}

ELISA plate was coated with total soluble proteins from the wild type and the transformed plants and purified NDV particles (commercial vaccine) at 37°C for one hour, followed by incubation with 1% bovine serum albumin (BSA) in PBS for 2 h at 37^ ^°C to prevent non-specific binding. The well was washed by PBST/PBS and incubated with anti-NDV serum. Afterwards, it was incubated with horseradish peroxidase conjugated with anti-rabbit IgG (1:1500). The anti-NDV serum was prepared after three times of immunization in rabbit with the inactivated V4 NDV particles and diluted at 1:1000 in PBST. Wells were developed with TMB substrate. The color reaction was stopped by 2N H2SO4 and read at 450 nm of wavelength.

3.3. Western Blot Assay {#sec2-3}
-----------------------

Total soluble protein (TSP) was extracted from transgenic tobacco plants as described by ([@ref4]). Briefly, 1gr of fresh leaves was ground in liquid nitrogen. One milliliter of extraction buffer was added, and the homogenate was centrifuged at 13,000 ×g for 15 min at 4 °C and the supernatant was used for further analysis. Protein samples were resolved by 15% SDS-polyacrylamide gel electrophoresis and transferred onto PVDF at 130 mA for 2 h. To prevent nonspecific antibody reactions, the membrane was blocked with BSA. After blocking with BSA, the membrane was washed using PBST/PBS, and incubated with horseradish peroxidase conjugated with anti his tag. After washing three times, the reaction was developed by addition of the TMB.

3.4. Induction of Immune Response in Rabbit {#sec2-4}
-------------------------------------------

Rabbits were immunized on days 0, 15, 29 and 50 with 500 µg of crude protein of wild type and transgenic plant (T26) emulsified in Incomplete Freund's adjuvant. Animals were then bled and the presence of anti-NDV specific antibodies in sera was determined by ELISA, in which the plates were coated with purified NDV.

4. Results {#sec1-4}
==========

4.1. Real-Time PCR {#sec2-5}
------------------

The results of real-time PCR are presented in **[Figure 1](#fig001){ref-type="fig"}**. As seen, the highest level of transgene transcription can be observed in lines T3, T12 and T26. This finding implies that lines T26, T12 had the highest expression level compared to others.

4.2. ELISA Assay {#sec2-6}
----------------

The results of ELISA assay are presented in **[Figure 2](#fig002){ref-type="fig"}**. As seen, the highest expression level was observed in lines T26, T12 and T3.

The lines with higher expression of the recombinant protein were used for further analyses. The assay was conducted in two replications.

4.3. Western-Blot Assay {#sec2-7}
-----------------------

Expression of HN-F fusion peptide in the transgenic lines was evaluated by the western-blot assay (**[Fig. 3](#fig003){ref-type="fig"}**). As can be seen in **[Figure 3](#fig003){ref-type="fig"}**, an about 10.6 kDa protein band appeared obviously in the transformed lines T26 and T12 whereas wild type and other transgenic lines showed no band.

4.4. Induction of Immune Response in Immunized Rabbit {#sec2-8}
-----------------------------------------------------

Rabbits were intraperitoneally immunized on days 0, 15, 29, and 50 with 500µg of the crude protein from the wild type and the transgenic plant (T26). Extract of non-transgenic plants was used in the control group. Animals were then bled and the sera was analyzed for the presence of anti-NDV antibodies in the ELISA assay. Antibodies produced in the experimentally-immunized Rabbit -i.e, Rabbit receiving transformed plant extracts- showed a strong response against NDV when tested in ELISA. No response was detected in the rabbits immunized with non-transformed plants (**[Fig. 4](#fig004){ref-type="fig"}**).

5. Discussion {#sec1-5}
=============

Production of therapeutic proteins including recombinant vaccines in plants represents an economical alternative to both traditional inactivation of infectious agents and the fermentation-based expression systems, especially for the production of high-volume reserves of subunit vaccines. Since the early 1990's, there have been numerous attempts to produce recombinant vaccines against various human and animal diseases in transgenic plant and various plant species have been investigated as the host for production of recombinant vaccines ([@ref1]). Oral delivery of antigens expressed in plant parts is possible because the plant cell wall provides an effective protection against degradation; consequently, much of the vaccine antigen expressed in the cells can reach the gut-associated lymphoid tissue (GALT) in an immunogenic form ([@ref8]). The property of plant cell walls in protecting the antigens from gastric digestion makes the plant systems ideal platforms for the production of recombinant vaccines ([@ref1]).

Although the traditional inactivated vaccines against ND are effective in protecting the animal, there are major disadvantages in using this vaccine that makes the development of alternative methods necessary ([@ref9]). In recent years, there have been extended efforts to develop new subunit vaccines against ND and other avian diseases ([@ref6], [@ref7], [@ref10], [@ref11]). Ge *et al*. (2013), for example, reported development of a chimeric recombinant vaccine that protects against Newcastle disease, as well as infectious bursal disease ([@ref9]).

Particularly, Hemagglutinin-Neuraminidase (HN) and Fusion (F) epitopes have been of interest for the development of anti-ND recombinant vaccines. For example, Lai *et al*. (2013) expressed hemagglutinin-neuraminidase protein in transgenic tobacco cells and used the recombinant protein for immunization of mice. The authors reported induction of specific anti-NDV antibodies in the mice receiving the recombinant protein ([@ref12]). Similarly, Yang *et al*. (2016) observed that recombinant infectious bronchitis virus expressing the hemagglutinin-neuraminidase (HN) protects chickens against NDV challenge ([@ref13]). Shahriari *et al*. (2015) expressed fusion (F) and haemagglutinin-neuraminidase (HN) epitopes in hairy roots of tobacco (Nicotiana tabaccum) to develop a scalable platform for production of anti-ND recombinant vaccines ([@ref14]).

Induction of immune response in animal host is the final step in every project concerning the development of recombinant vaccine. An antigen expressed in transgenic plant can be considered a potential recombinant vaccine only if its ability to induce immune response is approved through animal model trials ([@ref1]). In a pioneering work, Dalsgaard *et al*. (1997) demonstrated that subcutaneous injection of the recombinant VP2 vaccine expressed in black-eyed bean conferred protection against clinical disease in mink ([@ref15]). Alvarez *et al*. (2006) reported that plant-made subunit vaccine against plague was able to induce immune response in mice when administered orally ([@ref8]). Similarly, Chishester *et al*. (2012) reported that the recombinant Hemagglutinin-based influenza vaccine produced in transgenic plant induced strong immune response in animal model ([@ref16]).

In the present research, subcutaneous administration of the recombinant HN-F protein induced production of specific anti-ND antibodies in rabbits. This finding provides further support for the notion that plant-based recombinant vaccines are effective in induction of immune response in animal hosts. Our results match those reported by other authors. For example, Yang *et al*. (2007) expressed fusion glycoprotein of Newcastle disease virus in transgenic rice and observed that the recombinant protein is able to induce immune response in mice ([@ref17]). Berinstein *et al*. (2005) reported induction of both mucosal and systemic immunity in animal hosts as treated with recombinant protein expressed in potato ([@ref18]). Hahn *et al*. (2007) expressed hemagglutinin-neuraminidase protein of Newcastle disease virus in transgenic tobacco. The authors fed chickens with recombinant protein and observed induction of specific antibodies in the treated chickens ([@ref19]).

6. Conclusions {#sec1-6}
==============

The results obtained in this research indicated that recombinant vaccines generated in plant host possess high potential for the development of new generation of vaccines against Newcastle disease. We believe that our results provide additional support for the feasibility of using transgenic plants as an effective system for the production of recombinant vaccines. Application of other immunogenic sites of NDV capsid protein along with other kinds of promoters, enhancers, ribosome binding sites, signal peptides, and any molecular element involving in enhancement of foreign gene expression could be the subject of future studies.
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![ELISA analysis of transgenic plants. The wells surrounded by red circles indicates positive control, T3, T12 and T26 from left to right.](ijb-2019-01-e2215-g002){#fig002}

![Western-blot analysis of transgenic plants. T3: Protein sample of transgenic line T3, WT: Protein sample of wild type plant, T26: Protein sample of transgenic line T26, T12: Protein sample of transgenic line T12](ijb-2019-01-e2215-g003){#fig003}

![Induction of specific antibody in serum sample of rabbits injected with the transgenic plant extract; 1: The positive control (commercial vaccine), 2: The serum of rabbit immunized by injection of transgenic plant extract; 3: The serum of rabbit immunized by injection of Non-transformed Plants, 4: BSA](ijb-2019-01-e2215-g004){#fig004}
